Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

New Jersey

Cancer biologic therapy trials in New Jersey

77 cancer biologic therapy studies are recruiting participants at sites in 42 cities across New Jersey as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every New Jersey city with a recruiting study

By research area: Lung Cancer (26), Lymphoma (24), Breast Cancer (16), Melanoma (6), Prostate Cancer (5).

Hackensack (27), New Brunswick (26), Morristown (17), Middletown (14), Basking Ridge (13), Montvale (13), Long Branch (8), Camden (7), Paramus (7), Paterson (7), Jersey City (6), Lakewood (6), Moorestown (6), Newark (6), Voorhees Township (6), Englewood (5), Livingston (5), Neptune City (5), Sewell (5), Somerville (5), Toms River (5), Cherry Hill (4), Summit (4), Elizabeth (3), Flemington (3), Hamilton (3), Ridgewood (3), Belleville (2), East Brunswick (2), Mullica Hill (2), Red Bank (2), Brick (1), Florham Park (1), Hackettstown (1), Manahawkin (1), Newton (1), Pennington (1), Piscataway (1), Pompton (1), Saddle Brook (1), Teaneck (1), Vineland (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in New Jersey

Basic details from each study's public record (the 12 most recently updated of 77). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Flemington · Lakewood · Livingston · and 6 more U.S. locations
    Registry record
    NCT05564377 · updated
  2. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Florham Park
    Registry record
    NCT06393374 · updated
  3. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Hackensack
    Registry record
    NCT06841354 · updated
  4. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Hackensack · New Brunswick
    Registry record
    NCT06966700 · updated
  5. Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    New Brunswick
    Registry record
    NCT06686394 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in New Jersey on ClinicalTrials.gov.

Lung cancer: recently updated in New Jersey

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Mullica Hill · New Brunswick
    Registry record
    NCT06767514 · updated
  2. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Brick · Manahawkin · Neptune City · and 1 more U.S. location
    Registry record
    NCT07388524 · updated
  3. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Hackensack · Pennington
    Registry record
    NCT06422143 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in New Jersey on ClinicalTrials.gov.

Prostate cancer: recently updated in New Jersey

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Basking Ridge · Middletown · Montvale
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in New Jersey on ClinicalTrials.gov.

Lymphoma: recently updated in New Jersey

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Hackensack · Morristown · New Brunswick · and 1 more U.S. location
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Livingston · Long Branch · New Brunswick
    Registry record
    NCT06337318 · updated
  3. A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Morristown
    Registry record
    NCT05947851 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in New Jersey on ClinicalTrials.gov.

Ask about studies in New Jersey

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call